Share
181 Posts.
lightbulb Created with Sketch. 89
clock Created with Sketch. 03/05/25
16:55
Share
Originally posted by Silverchair:
↑
With less than two months until the books close on what looks like being the best ever financial performance of Clinuvel it's worth remembering the super half yearly results from just a couple of months back! Cash just flowing in and EPS up very nicely (27.1%) to hopefully surpass 80 cents per share this year - thought we might get some analyst upgrades after that result as I don't think even Jefferies with their recent $39.20 price target had those good results factored in. NPAT after tax up a very solid 28.7% which is great and I like the Profit before tax which was up 48.1% to nearly $22 Million in what is the weaker half by far for Clinuvel due to seasonality. The extra expenses for running a blockbuster phase 3 trial slated for completion this year are fine - have you ever heard of such a small/tiny Biotech running an absolute blockbuster phase 3 trial while consistently growing profits? No need to partner up with Big Pharma. It's looking great and if successful will be transformational for Clinuvel taking great profits to exceptional profits I hope - even if just half of Clinuvel financial forecasts for Vitiligo are achieved. All IMO DYOR
Expand
„ running a blockbuster phase 3 trial “
(20min delay)